A comparison of macrophage migration inhibitory factor with C reactive protein in diabetic hypertensive patients with myocardial infarction that underwent primary percutaneous coronary intervention.
Resumen
The inflammatory response is one of the complications of diabetic hypertensive patients with myocardial infarction (MI). The purpose of this study was to determine the diagnostic value of macrophage migration inhibitory factor (MIF) compared with high sensitivity C reactive protein (hs-CRP) in diabetic hypertensive patients presented with MI; and to determine the concomitant association between these factors in MI patients. For this purpose, 100 patients with MI were categorized into four groups, according to the existence of diabetes mellitus (DM) and/or hypertension (HTN), with 38 subjects with normal angiography considered as the control group. The levels of MIF and hs-CRP were estimated quantitatively using a sandwich enzyme-linked immunosorbent assay and a particle-enhanced immune turbidimetric assay, respectively. In addition, lipid profiles, hematological indicators, and certain clinical features were compared among the studied groups. The levels of MIF and hsCRP increased significantly in MI patients compared to the controls (p<0.05). Additionally, the levels of MIF differed significantly between all MI groups and the control group (p<0.05). Although the group DM-HTN showed the highest MIF level within the MI groups, the difference was not significant (p>0.05). However, the hs-CRP level showed a significant difference (p<0.05). In addition, the MIF level correlated positively with hs-CRP, leukocytes, and neutrophils (p<0.05). Both MIF and hs-CRP levels correlated positively with age, body mass index (BMI), total cholesterol, triglyceride, low-density lipoprotein-cholesterol (LDL-C) and non-high density lipoprotein (HDL), but they correlated negatively with HDL-C. According to the results, although MIF was a valuable diagnostic marker for MI, the hs-CRP showed to be a better prognostic indicator than MIF in diabetic hypertensive patients that presented MI.
Descargas
Citas
Libby P. History of discovery inflammation in atherosclerosis. Arter Thromb Vasc Biol 2013; 32:2045–51.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: system- atic analysis of population health data. Lan- cet 2006; 1747–1757.
Lee MG, Jeong MH, Lee KH, Park KH, Sim DS, Yoon HJ, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary in- tervention. J Cardiol Japanese College of Cardiology 2012; 60: 257–263.
Müller II, Müller KA, Karathanos A, Schönleber H, Rath D, Vogel S, Chat- terjee M, Schmid M, Haas M, Seizer P, Langer H, Schaeffeler E, Schwab M, Ga- waz M, Geisler T. Impact of counterbal- ance between macrophage migration inhibitory factor and its inhibitor Grem- lin-1 in patients with coronary artery dis- ease. Atherosclerosis 2014; 237: 426–432.
Gao XM, Liu Y, White D, Su Y, Drew BG, Bruce CR, Kiriazis H, Xu Q, Jennings N, Bobik A, Febbraio MA, Kingwell BA, Bu- cala R, Fingerle-Rowson G, Dart AM, Mo- rand EF, Du XJ. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia–reperfusion in- jury. J Mol Cell Cardiol 2011;50(6): 991– 999.
White DA, Fang L, Chan W, Morand EF, Kiriazis H, Duffy SJ, Taylor AJ, Dart AM, Du XJ, Gao XM. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PLoS ONE 2013;8(10): e76206.
Backes JM, Howard PA MP. Role of C-reac- tive protein in cardiovascular disease. Ann Pharmacother 2004; 38: 110–118.
Bonow RO, Louis S, Mann DL, Libby P. Heart Disease Braunwald’S. 9th ed. Phila- delphia; 2011; 934-938.
Mendis S, Thygesen K, Kuulasmaa K, Gi- ampaoli S, Mahonen M, Ngu Blackette K, Lisheng L. World Health Organization definition of myocardial infarction: 2008 – 09 revision. Int J Epidemiol 2011; 40: 139–146.
World Health Organization. Use of Glycat- ed Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus - NCBI Bookshelf 2011.
Kamińska J, Koper OM, Siedlecka-Czykier E, Matowicka-Karna J, Bychowski J, Ke- mona H. The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. Saudi J Biol Sci 2016; 1263–1271.
Yüksel A, Bilgir F, Bilgir O, Calan M, Boz- kaya G. Increased circulating macrophage migration inhibitory factor levels are asso- ciated with coronary artery disease. Clinics 2015; 70: 169–172.
Peppes V, Rammos G, Manios E, Koroboki E, Rokas S, Zakopoulos N. Correlation between myocardial enzyme serum levels and markers of inflammation with sever- ity of coronary artery disease and Gensini score: A hospital-based, prospective study in Greek patients. Clin Interv Aging 2008; 3: 699–710.
Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C Expression of macrophage migration in- hibitory factor in different stages of human atherosclerosis. Circulation 2002; 105: 1561–1566.
Fan F, Fang L, Moore XL, Xie X, Du XJ, White DA, O’Brien J, Thomson H, Wang J, Schneider HG, Ellims A, Barber TW, Dart AM. Plasma macrophage migration inhibi- tor factor is elevated in response to myo- cardial ischemia. J Am Heart Assoc 2016;5: e003128. doi: 10.1161/JAHA.115.003128.
Calandra T, Roger T. Macrophage migra- tion inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791–800.
Suleiman M, Khatib R, Agmon Y, Maha- mid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive pro- tien. J Am Coll Cardiol 2006; 47: 962–968.
James SK, Lindahl B, Siegbahn A, Strids- berg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wal- lentin L. N-terminal pro–brain natriuretic peptide and other risk markers for the sepa- rate prediction of mortality and subsequent myocardial infarction in patients with un- stable coronary artery disease. A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275–281.
Zhou B, Ren C, Zu L, Zheng L, Guo L, Gao W. Elevated plasma migration inhibitory factor in hypertension–hyperlipidemia pa- tients correlates with impaired endothelial function. Med 2016; 95: e5207.
Müller KA, Rath D, Schmid M, Schoenle- ber H, Gawaz M, Geisler T, Müller II. High plasma levels of gremlin-1 and macrophage migration inhibitory factor, but not their ratio, indicate an increased risk for acute coronary syndrome in patients with Type 2 diabetes mellitus. Clin Cardiol 2016; 39: 201–206.
Kumpatla S, Karuppiah K, Immaneni S, Muthukumaran P, Krishnan J, Narayana- moorthy SK, Viswanathan V. Comparison of plasma adiponectin & certain inflamma- tory markers in angiographically proven coronary artery disease patients with & without diabetes. Indian J Med Res 2014; 139: 841–850.
Chan W, White DA, Wang XY, Bai RF, Liu Y, Yu HY, Zhang YY, Fan F, Schneider H G, Duffy SJ, Taylor AJ, Du XJ, Gao W, Gao XM, Dart AM. Macrophage migration in- hibitory factor for the early prediction of infarct size. J Am Heart Assoc 2013; 2(5):e000226.
Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflam- matory effects of statins on coronary artery disease: An updated review of the literature. Curr Cardiol Rev 2017; 13(3):209-216.
Yasue H, Hirai N, Mizuno Y, Harada E, Itoh T, Yoshimura M, Kugiyama K, Ogawa H. Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J 2006; 70(1):8-13.
Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S Fu M. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004; 126(5):1417-1422.
Yu CH-M, Lau Ch-P,Lai KW-H, Huang X-R, Chen W-H, and Lan HY. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial in- farction. Am J Cardiol 2001; 88: 774–777.
Boekholdt SM, Peters RJ, Day NE, Lu- ben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coro- nary artery disease in adults without prior myocardial infarction or stroke: the EPIC- Norfolk Prospective Population study. Am J Med 2004; 117: 390–397.
